Yifan Pharmaceutical's addiction treatment meets phase Ib targets

Yifan Pharmaceutical announced its investigational detoxification capsule met expected targets in Phase Ib clinical trials for opiate addiction recovery, showing good safety and tolerability profiles.

The treatment demonstrated a positive trend in preventing relapse and improving behavioral control compared to placebo. Yifan has invested approximately RMB 98.283 million in development and received breakthrough therapy designation in July 2025.